Cancer Research Donn Young  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 45, 1474-1478, April 1, 1985]
© 1985 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hosoi, J.
Right arrow Articles by Kuroki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosoi, J.
Right arrow Articles by Kuroki, T.

Regulation of Melanin Synthesis of B16 Mouse Melanoma Cells by 1{alpha},25-Dihydroxyvitamin D3 and Retinoic Acid1

Junichi Hosoi, Etsuko Abe, Tatsuo Suda and Toshio Kuroki2

Department of Cancer Cell Research, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo 108 [J. H., T. K.], and Department of Biochemistry, School of Dentistry, Showa University, Hatanodai, Shinagawa-ku, Tokyo 142 [E. A., T. S.], Japan

Melanin synthesis of B16 mouse melanoma cells was found to be stimulated dose and time dependently by 1{alpha},25-dihydroxyvitamin D3 [1{alpha},25(OH)2D3], the hormonal form of vitamin D3. The stimulation of melanogenesis resulted from an increase in the activity of tyrosinase, a key enzyme in melanin synthesis. The minimum dose required for this stimulation was as low as 0.05 ng/ml, or 0.12 nM, a physiological level of plasma 1{alpha},25(OH)2D3. The stimulation by 1{alpha},25(OH)2D3 was specific; other derivatives of vitamin D3 caused no stimulation at a concentration of 500 ng/ml. When the cells were plated on agar plates, the proportion of dark or black colonies was not increased by the exposure to 1{alpha},25(OH)2D3. Furthermore, this compound did not induce melanin synthesis of an amelanotic variant. Thus, its stimulatory effect seemed to be due to stimulation of melanin synthesis of melanotic cells, rather than to conversion of amelanotic clones to melanotic ones. 1{alpha},25(OH)2D3 did not induce intracellular cyclic adenosine 3':5'-monophosphate, while cholera toxin induced cyclic adenosine 3':5'-monophosphate and stimulated melanin synthesis and tyrosinase activity much more than did 1{alpha},25(OH)2D3, suggesting that 1{alpha},25(OH)2D3 stimulates melanin synthesis by a cyclic adenosine 3':5'-monophosphate-independent mechanism.

B16 melanoma cells contained specific receptors for 1{alpha},25(OH)2D3. Scatchard plot analysis revealed two types of receptor; the high-affinity receptor had a Kd of 18.3 pM and an Nmax of 10.6 fmol/mg of protein. The specificity of receptor binding was demonstrated by studies showing that, for 50% displacement of 1{alpha},25(OH)2D3 binding, other derivatives were required at 500 times higher concentrations or more.

In contrast to 1{alpha},25(OH)2D3, retinoic acid inhibited melanin synthesis and tyrosinase activity of B16 melanoma cells dose and time dependently. On simultaneous treatment, 1{alpha},25(OH)2D3 and retinoic acid caused mutual interference, and a balance between their respective stimulating and inhibitory effects was obtained at a molar ratio of 10:1; i.e., with 10 nM 1{alpha},25(OH)2D3 and 1 nM retinoic acid.

1 Supported in part by a Grant for Cancer Research from the Ministry of Education, Science and Culture of Japan.

2 To whom requests for reprints should be addressed.

Received 7/31/84. Revised 11/29/84. Accepted 12/19/84.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
S. E. Christensen, P. H Nissen, P. Vestergaard, L. Heickendorff, L. Rejnmark, K. Brixen, and L. Mosekilde
Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism
Eur. J. Endocrinol., December 1, 2008; 159(6): 719 - 727.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. Slominski, D. J. Tobin, S. Shibahara, and J. Wortsman
Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation
Physiol Rev, October 1, 2004; 84(4): 1155 - 1228.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
H. Ando, Y. Funasaka, M. Oka, A. Ohashi, M. Furumura, J. Matsunaga, N. Matsunaga, V. J. Hearing, and M. Ichihashi
Possible involvement of proteolytic degradation of tyrosinase in the regulatory effect of fatty acids on melanogenesis
J. Lipid Res., July 1, 1999; 40(7): 1312 - 1316.
[Abstract] [Full Text]


Home page
J. Cell Sci.Home page
C Romero, E Aberdam, C Larnier, and J. Ortonne
Retinoic acid as modulator of UVB-induced melanocyte differentiation. Involvement of the melanogenic enzymes expression
J. Cell Sci., January 4, 1994; 107(4): 1095 - 1103.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1985 by the American Association for Cancer Research.